CD274 and non-small cell lung carcinoma: It has also been suggested that some chemotherapy agents, including cisplatin combined with gemcitabine or docetaxel and carboplatin combined with paclitaxel or pemetrexed, activate the immune response of NSCLC patients, since PD-L1 and specific T-cells are higher in NSCLC resected tumors that received neoadjuvant chemotherapy compared to chemo-naïve tumors [32].